Ethicon, Inc.

Appointments reflect ARTBIO's commitment to utilizing world-class experience and insights needed to advance alpha radioligand programs Company Co-founder Roy Larsen, Ph.D. will transition from Board of Directors to a new Technical Advisory Board within ARTBIO CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced four appointments to its Board of Directors: Maha Katabi, Ph.D., CFA is a General Partner at Sofinnova Investments. With more than two decades of experience in managing public and private biotech companies, Dr. Katabi will advise ARTBIO in their work to maximize investments for operations and growth strategies. Dr. Katabi received a Ph.D. in Pharmacology at McGill University and is a CFA Charterholder. Dr. Katabi was part of the early investment syndicate at RayzeBio, which was acquired by BMS in 2024. She currently serves on several public and private company boards. Robert Mittendorff, M.D., MBA is a General Partner and Head of Healthcare at B Capital Group, a global investment firm. His 20 years of experience as both a physician and public company executive will support ARTBIO's program expansion strategy. Dr. Mittendorff received his M.D. from Harvard University and MIT in the HST Program, and his MBA from Harvard Business School. Prior to B Capital Group, Dr. Mittendorff worked at Hansen Medical Inc., Merck, Boston Consulting Group, and at Kaiser Permanente. Julie O'Neill, MBA (Independent Director) is an experienced healthcare leader, having held senior manufacturing and operations roles at Alexion Pharmaceuticals and Gilead Sciences. She also chairs the board of Ireland's National Institute for Bioprocessing Research and Training. Mrs. O'Neill holds a Bachelor of Science in Pharmacy from Trinity College Dublin, an MBA from University College Dublin, and is a Chartered Director of The Institute of Directors in Ireland. Mrs. O'Neill serves on the boards of ICON plc, DBV Technologies, and Advancion Sciences (formerly Angus Chemical Company). Gabe Gelman has served as Head of Capital Solutions at Baker Bros. Advisors LP since 2025. Prior to joining Baker Brothers, Mr. Gelman had a 25-year career at Goldman Sachs where he most recently served as Head of Equity Capital Markets in the Americas. While at Goldman Sachs, Mr. Gelman advised on and led many high-profile biotechnology financings. Mr. Gelman holds a B.S.E. in Industrial Engineering from the University of Michigan. "Following our recent Series B funding round, these appointments will enable ARTBIO to rapidly advance multiple programs designed to have the highest patient impact," said Ted W. Love, M.D., Chairman of the Board at ARTBIO. "We're incredibly fortunate to have Maha, Robert, Julie and Gabe's perspectives informing the key stages of strategic growth at ARTBIO." Dr. Roy Larsen co-founded ARTBIO in 2021 and is a pioneer in the field of radiopharmaceuticals. With these latest board appointments, Dr. Larsen will transition into ARTBIO's newly created Technical Advisory Board. His dedication and ongoing partnership with ARTBIO are invaluable. "Dr. Larsen is a pillar of the radiopharma field – thousands of patients have benefited from his inventions already and his innovations will continue to have a positive impact on ARTBIO and the entire RLT industry for decades to come," said Emanuele Ostuni, CEO of ARTBIO. "I'm proud to call Roy a mentor and friend and look forward to our ongoing collaboration to bring novel cancer therapies to market." About ARTBIO ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 in metastatic castration resistant prostate cancer currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit , and follow us on LinkedIn. SOURCE ARTBIO WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

This recall involve correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction. Affected Product Product Names: Endopath Echelon Vascular White Reload for Advanced Placement Tip (35mm, 4 row); Product code VASECR35 Unique Device Identifier (UDI)/Model: 10705036014591 Affected Lots: 917C65, 895C93, 918C15, 938C92, 936C69, 929C38, 948C78, 990C81, 979C81, 400D82, 962C74, 506D29, 379D80, 413D56, 418D41, 419D47, 415D43, 427D07, 434D35, 442D78, 442D83, 444D96, 456D87, 455D03, 493D27, 468D88, 482D30, 502D90, 489D62, 134D80, 112D03, 155D33, 159D49, 181D11, 194D77, 125D04, 167D13, 223D59, 175D72, 234D11, 238D70, 261D10, 270D69, 317D74, 194D76, 349D54, 347D73, 317D73, 356D54, 326D66, 319D76, 338D99, 336D39, 356D53, 367D26, 378D04, 214D1 What to Do Confirm that all personnel using Endopath Echelon Vascular White Reload for Advanced Placement Tip (35 mm, 4 Row), product code VASECR35, understand the Instructions for Use (IFU) for the Echelon Flex Powered Vascular Stapler (product code PVE35A). Scan the QR Code below or follow the link provided for a video demonstration on how to manage a device lockout. Note: Technical support can be accessed 24/7 by calling 1-877-ETHICON (1-877-384-4266) option 4. Watch on YouTube On April 22, 2025, Ethicon sent all affected customers an Urgent Medical Device Correction letter recommending the following actions: Share the notification with all users of Endopath Echelon Vascular White Reload for Advanced Placement Tip (35 mm, 4 Row), product code VASECR35. Post a copy of this communication. If any subject product has been forwarded to another facility, contact that facility to share this information. Complete the Business Reply Form confirming receipt of this notice within three business days. Reason for Correction Ethicon Endo-Surgery is correcting this product due to an inadvertent lockout during surgical procedures. The device will momentarily activate but will not cut or staple tissue. Additional steps will be required to open it and remove it from tissue. The device has been designed such that an instrument lockout event should not lead to patient harm. During a lockout, the device may briefly activate but will not cut or staple tissue, requiring additional steps to release and remove it safely. The knife does not advance far enough to cut, staples remain below the tissue contact surface, and a built-in gap between the anvil and staple cartridge face helps prevent vessel injury during clamping and unclamping. A representative from Ethicon Endo-Surgery, LLC will be contacting customers to ensure familiarity with all aspects of the Echelon Flex Powered Vascular Stapler instructions for use. The use of affected product may cause serious adverse health consequences, including life-threatening hemorrhage, surgical delay, and death. There has been one reported death and one injury related to this issue. Device Use The Echelon Flex Powered Vascular Stapler with Advanced Placement Tip and Endopath Echelon Vascular White Reload for Advanced Placement Tip (35mm, 4 Row) reloads are sterile, single patient use devices that simultaneously cut and staple tissue. There are four staggered rows of staples, two on either side of the cut line. This reload is used exclusively with the Echelon Flex Powered Vascular Stapler, product code PVE35A. The instrument’s lockout feature is designed to prevent a used or improperly installed reload from being fired, or an instrument from being fired without a reload. Contact Information Customers in the U.S. with questions about this recall should contact the Ethicon Resource Department at 1-877-ETHICON (1-877-384-4266). Additional FDA Resources: Unique Device Identifier (UDI) The unique device identifier (UDI) helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified, and problems potentially corrected more quickly. How do I report a problem? Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of: 07/25/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

AKRON, Ohio, March 26, 2025 /PRNewswire/ -- Resivant Medical today announced that Jeff Clark, a longtime leader in the medical device industry, was elected to its Board of Directors by the company's shareholders. "We are extremely pleased to welcome Jeff to our board," said Resivant Medical Board Chairman Russ Donda. "Jeff's 30+ years of experience as a leader in surgical adhesive and medical device development and commercialization will be invaluable as we continue to execute our mission to bring the game-changing Cutiva™ adhesive platform to market to help patients in the U.S. and beyond." Mr. Clark served as CEO of HyperBranch Medical Technology where he led the development of Adherus AutoSpray Dural Sealant which was successfully commercialized worldwide and later acquired by Stryker Corp in 2018. Earlier in his career, Mr. Clark was vice president of research and development at Closure Medical Corporation, where he led the development of the Dermabond topical skin adhesive. This was the first topical skin adhesive approved by the U.S. Food and Drug Administration (FDA), and the company was acquired by Ethicon, a Johnson & Johnson Company. About Resivant Medical: Resivant Medical, a pioneer in the field of medical adhesives, has developed groundbreaking adhesive technology that enhances usability and performance for both patients and healthcare professionals. Its range of skin closure adhesive products is designed for topical application on wounds and surgical incisions. Resivant has received U.S. FDA 510(k) clearance for its first two products, Cutiva™ Topical Skin Adhesive, and Cutiva PLUS™ Skin Closure System. The global skin closure market, encompassing both traditional and advanced surgical closure methods, was valued at approximately USD $14.4 billion in 2024 and is anticipated to experience significant growth in the coming years. For more information, visit Email: [email protected] Media inquiries: Kelly Arledge, +1.614.205.0339 SOURCE Resivant Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED